1. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone

2. Panelists

3. Case Study: 58-Year-Old Male

4. Incidence of MI in Subjects With T2DM vs the Nondiabetic CAD Population

5. Is Type 2 Diabetes a Coronary Risk Equivalent?

8. Risk for Cardiovascular Events Is Greatest When Both Diabetes and CKD Are Present

9. Mortality Risk Doubles in Comorbid T2DM and CKD*

10. All-Cause and Cardiovascular Mortality by eGFR in Subjects With and Without Diabetes

11. All-Cause Mortality by eGFR in Subjects With and Without Diabetes and Hypertension

12. Effect of Intensive Glucose Control on Major Cardiovascular Events

13. Effect of Intensive Glucose Control on All-Cause Mortality

14. Effect of Intensive Glucose Control on Major CV Events by History of Macrovascular Disease

15. PPAR-a and PPAR-g Agonists: Target Systems

16. TZDs: Renal Function in Patients With Baseline Normo- and/or Microalbuminuria and T2DM

17. CV Events With PPAR-g Agonists

18. PROactive: Effect of Pioglitazone on CV Outcomes in T2DM Patients by CKD Status

19. VA-HIT: Effect of Gemfibrozil on Cardiac Events in Secondary Prevention

20. VA-HIT: Effect of Gemfibrozil on CV Events and Death in Patients With CRI

21. FIELD: Long-Term Effect of Fenofibrate on Albuminuria in T2DM

23. ACCORD Lipid: Effect of Statin Plus Fenofibrate vs Statin Alone on Markers of Renal Function

24. ACCORD Renal Ancillary Study: Reversibility of Fenofibrate-Related Renal Function Impairment

25. Fenofibrate Treatment in Type 2 Diabetes: Effect on Renal Function

26. Effects of Fibrates on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

27. Fibrates: Is High TG, Low HDL-C the Optimal Patient Type?

28. Dual PPAR-a/g Agonists

29. Targets of Glucose-Lowering Drugs

31. Impact of Intensive Glycemic Control in Subjects With CKD: Micro- and Macroalbuminuria

32. Impact of Intensive Glycemic Control in Subjects With CKD: Serum Creatinine

33. Impact of Intensive Glycemic Control in Subjects With CKD: All-Cause and CV Mortality

34. Impact of Intensive Glycemic Control in Subjects With CKD: End-Stage Renal Disease

35. NKF Diabetes and CKD Systematic Review Conclusions

36. STENO-2: Multifactorial Risk Factor Management in Type 2 Diabetes

37. STENO-2: All-Cause Mortality

40. Dual a/g PPAR Agonist: Effect of Muraglitazar on A1c and Lipid Levels

41. Muraglitazar Clinical Development

42. Effect of Muraglitazar on All-Cause Mortality and MACE in Patients With T2DM

43. GALLANT 8: Effect of Tesaglitazar on Top of Metformin vs Metformin Alone on A1c

44. GLAD: Effect of Tesaglitazar vs Pioglitazone on Lipid Measures

45. Effect of Tesaglitazar on Serum Creatinine and Glomerular Filtration

46. Tesaglitazar Clinical Development

47. SYNCHRONY: Effect of Aleglitazar vs Pioglitazone on LDL-C and HDL-C

48. SYNCHRONY: Effect of Aleglitazar vs Pioglitazone on A1c and FPG

49. SYNCHRONY: Effect of Aleglitazar on Markers of Renal Function

50. SESTA R: Impact of Supratherapeutic Doses of Aleglitazar on Renal Function in T2DM

51. ALENEPHRO: Aleglitazar Phase 2 Renal Function Study

52. ALENEPHRO: Preliminary Details

53. Expected Targets for Dual PPAR-a/g Agonists

54. Effect of Aleglitazar on Cardiometabolic Risk

55. ALECARDIO: Aleglitazar in Patients With T2DM and ACS

56. Blood Glucose-Lowering Agents and Cardiovascular Risk Management

57. Program Summary